[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-460700-105":59,"doc-detail-460700-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","an-interventional-study-on-the-late-treatment-of-severe-bronchopulmonary-dysplasia-in-preterm-infants-using-mesenchymal-stromal-cells","An Interventional Study on the Late Treatment of Severe Bronchopulmonary Dysplasia in Preterm Infants Using Mesenchymal Stromal Cells","","Background: Bronchopulmonary dysplasia (BPD) remains a major management challenge in preterm infants, and conventional approaches have not reduced its prevalence. Mesenchymal stromal cell (MSC) therapy shows favorable safety in earlier trials, but evidence for late-term treatment of established severe BPD is limited. Aim: Assess outcomes after MSC therapy in seven extremely preterm infants with severe established BPD. Methods: A retrospective cohort of seven infants received MSC cycles via intratracheal and intravenous routes, initiated between postnatal days 32 and 84.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/an-interventional-study-on-the-late-treatment-of-severe-bronchopulmonary-dysplasia-in-preterm-infants-using-mesenchymal-stromal-cells/460700/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/an-interventional-study-on-the-late-treatment-of-severe-bronchopulmonary-dysplasia-in-preterm-infants-using-mesenchymal-stromal-cells/460700.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the study aim regarding MSC therapy for severe BPD?","Question",{"text":113,"@type":114},"The study aimed to investigate outcomes in seven extremely preterm infants who received MSC therapy for severe established BPD.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were MSCs administered and scheduled in the treatment protocol?",{"text":118,"@type":114},"MSC therapy used intratracheal injection of 1 million cells per kilogram per cycle plus intravenous infusion of an additional 0.5 million cells per kilogram. Treatment began between postnatal days 32 and 84, with some infants receiving two cycles and others receiving three to four weekly cycles.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the main findings about weaning from respiratory support?",{"text":122,"@type":114},"All infants were successfully extubated to nCPAP after MSC treatment. Infants receiving three to four cycles were weaned off ventilators and discharged home without supplemental oxygen, while two infants who received two cycles could not be weaned off respiratory support.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},460700,1790795046,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Wiley  \nStem Cells International  \nVolume 2026, Article ID 2715294, 10 pages [https://doi.org/10.1155/sci/2715294](https://doi.org/10.1155/sci/2715294)  \nResearch Article  \nAn Interventional Study on the Late Treatment of Severe Bronchopulmonary Dysplasia in Preterm Infants Using Mesenchymal Stromal Cells  \nSukran Yildirim   \nNeonatology Clinic, University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Türkiye  \nCorrespondence should be addressed to Sukran Yildirim; [drsukranyildirim@yahoo.com](drsukranyildirim@yahoo.com)  \nReceived 16 July 2025; Revised 30 November 2025; Accepted 16 December 2025  \nAcademic Editor: Ludovic Zimmerlin  \nCopyright © 2026 Sukran Yildirim. Stem Cells International published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \nBackground: Bronchopulmonary dysplasia (BPD) remains a signiﬁcant challenge in the management of preterm infants. Although conventional treatment approaches have helped reduce the morbidity associated with BPD, the prevalence of the condition has not decreased, highlighting an urgent need for new therapies. Mesenchymal stromal cell (MSC) therapy has emerged as a potentially promising intervention, showing a favorable safety proﬁle in Phase II clinical trials. However, research on the use of MSCs as a late-term therapeutic strategy for established BPD is still in its early stages, indicating a need for further studies to evaluate their effectiveness and optimal application.  \nAim: To investigate the results of seven extremely preterm infants who underwent an MSC therapy for severe established BPD. Method: A cohort of seven infants diagnosed with severe BPD (sBPD) received MSC therapy to assist in their transition to spontaneous breathing. For the ﬁrst six infants, MSC therapy was discontinued after extubation; however, the ﬁnal infant continued to receive MSC therapy as he remained on nasal continuous positive airway pressure (nCPAP) .  \nEach treatment cycle involved administering 1million MSCs per kilogram via intratracheal injection, along with an additional 0.5million MSCs delivered through intravenous infusion. Treatment was initiated between postnatal days 32 and 84. The ﬁrst three infants each underwent two treatment cycles, the fourth infant received three cycles, and the last three infants were scheduled for  \n4 weekly cycles. A retrospective analysis was conducted to evaluate the outcomes of the therapy.  \nResults: All infants were successfully extubated to nCPAP following MSC treatment. However, two infants who underwent two cycles of MSC therapy could not be weaned off respiratory support. In contrast, all infants who received three to four cycles were successfully weaned off the ventilators and discharged home without the need for supplemental oxygen. Additionally, secondary beneﬁts were observed, including improvements in intraventricular hemorrhage (IVH) and retinopathy of prematurity (ROP), a decrease in the number of packed red blood cell transfusions, and fewer episodes of sepsis.  \nConclusions: Our ﬁndings indicate that administering up to four treatment cycles may be more effective for the long-term management of sBPD. Additionally, using MSCs through both intratracheal and intravenous routes could offer beneﬁts beyond just the lungs, highlighting an area for further research.  \nKeywords: BPD; late treatment; mesencymal stromal cell; prematurity  \n1. Introduction  \nMesenchymal stromal cells (MSCs) play a crucial role in regenerative medicine due to their ability to replicate, differentiate, and migrate to injured tissues, making them ideal candidates for tissue regeneration [1]. Recent research has shown that the  \nprimary regenerative effects of MSCs are mediated through their paracrine activity, which involves the release of extracellular vesicles [2] . This ","cbCaieuXsWkXQjX5","https://ap.wps.com/l/cbCaieuXsWkXQjX5","pdf",433636,"English","# Introduction\n## Background and Rationale\n# Aim and Method\n## Study Cohort and Treatment Cycles\n## Administration Routes and Dosage\n## Outcome Assessment\n# Results\n# Conclusions","[{\"question\":\"What was the study aim regarding MSC therapy for severe BPD?\",\"answer\":\"The study aimed to investigate outcomes in seven extremely preterm infants who received MSC therapy for severe established BPD.\"},{\"question\":\"How were MSCs administered and scheduled in the treatment protocol?\",\"answer\":\"MSC therapy used intratracheal injection of 1 million cells per kilogram per cycle plus intravenous infusion of an additional 0.5 million cells per kilogram. Treatment began between postnatal days 32 and 84, with some infants receiving two cycles and others receiving three to four weekly cycles.\"},{\"question\":\"What were the main findings about weaning from respiratory support?\",\"answer\":\"All infants were successfully extubated to nCPAP after MSC treatment. Infants receiving three to four cycles were weaned off ventilators and discharged home without supplemental oxygen, while two infants who received two cycles could not be weaned off respiratory support.\"}]","An Interventional Study on the Late Treatment of Severe Bronchopulmonary Dysplasia in Preterm Infants Using Mesenchymal Stromal Cells | PDF",1790759150,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/7d7f34f10d668c510ac4b669a3c4cae2.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/13229534e06d60eeeb1279516a2c4f99.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/686b184d217bb9c84e4ba4a4925cad93.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/1345d136b0e38fb1b8f7a2bd6d01fe62.webp",980,1306]